Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03263052 · ClinicalTrials.gov registry record
Converting Elderly Kidney Transplant Recipients From Tacrolimus to Envarsus to Limit Neurological AE and Improve QOL
A clinical trial, sponsored by University of Illinois at Chicago.
- Completed
- Registry status
- 40
- Enrollment target
NCT03263052 is a clinical trial that has completed, run by University of Illinois at Chicago. The registered enrollment target is 40 participants.
The verdict
NCT03263052 has completed, sponsored by University of Illinois at Chicago.
- COMPLETED
- Registry status
- 40 participants
- Enrollment target
Study Summary
This study will investigate whether converting patients from FDA approved immediate-release tacrolimus to FDA approved extended release tacrolimus (Envarsus) reduces neurological side-effects, improves quality of life, and enhances adherence. A select group of elderly (\> 60 years of age) patients, who are especially sensitive to tacrolimus-related adverse (AEs) effects, will be provided the opportunity to convert to Envarsus with this study.
Interventions
- DRUG Tacrolimus XR (Envarsus)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2017-07-01 |
| Est. Completion | 2020-01-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03263052
The ClinicalTrials.gov registry entry for NCT03263052 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Illinois at Chicago, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tacrolimus XR (Envarsus) is the first listed.
NCT03263052 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03263052 about?
NCT03263052 is a clinical study titled "Converting Elderly Kidney Transplant Recipients From Tacrolimus to Envarsus to Limit Neurological AE and Improve QOL". This study will investigate whether converting patients from FDA approved immediate-release tacrolimus to FDA approved extended release tacrolimus (Envarsus) reduces neurological side-effects, improves quality of life, and enhances adherence. A select group of elderly (\> 60 years of age) patients, ...
What is the current status of trial NCT03263052?
This trial is currently completed. The enrollment target is 40 participants. The study started on 2017-07-01. Estimated completion is 2020-01-01.
What interventions are being tested in trial NCT03263052?
The interventions under investigation include: Tacrolimus XR (Envarsus) (DRUG).
Who is sponsoring clinical trial NCT03263052?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.